Zhu Jinying, Xiong Ping, Wang Wei, Lu Tianshu, Ouyang Defang
State Key Laboratory of Mechanism and Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau 999078, China.
State Key Laboratory of Mechanism and Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau 999078, China; Department of Public Health and Medicinal Administration, Faculty of Health Sciences (FHS), University of Macau, Macau 999078, China.
J Control Release. 2025 Oct 10;386:114123. doi: 10.1016/j.jconrel.2025.114123. Epub 2025 Aug 16.
Amorphous solid dispersions (ASDs) have emerged as a pivotal strategy in enhancing the dissolution profiles of poorly water-soluble drugs. Although the apparent dissolution rate (both molecular and colloidal drugs) within ASDs has been determined in past experiments, only molecular drugs in the dissolution can be effectively absorbed in vivo. This study aims to develop a prediction model for the in vitro (molecular dissolution) and in vivo (systemic absorption) fate of ASD formulations by integrating artificial intelligence and physiologically based pharmacokinetic (AI/PBPK) modeling. 238 ASD formulations, including 22 small-molecule drugs and 1693 drug molecular dissolution time points, were collected for molecular dissolution prediction. The Tabular Prior Data Fitted Networks (TabPFN) model exhibited robust predictive performance across six machine learning frameworks, achieving a low root mean squared error (RMSE) of 0.116 ± 0.020 and a high determination coefficient (R) of 0.905 ± 0.028. Then, the release kinetic model bridges the in vitro and in vivo dissolution of ASDs. The PBPK models of three on-market ASDs (Noxafil®, Prograf®, Gris-PEG®) were developed and validated with the absolute average fold error (AAFE) of less than 2. The simulated systemic absorption exhibits high similarity to the results obtained using the classical deconvolution method, with a similarity factor (f) exceeding 50. An additional 37 marketed ASD formulations were evaluated using our framework, with most of the Cmax and AUC predictions falling within two-fold error ranges, demonstrating the high accuracy and robustness of our ASD AI/PBPK model. This research not only provides a practical and rapid computational tool for the rational design and evaluation of ASDs but also significantly advances our understanding of the interplay between molecular dissolution and systemic absorption, thus contributing to the optimization of drug delivery systems.
无定形固体分散体(ASDs)已成为提高难溶性药物溶出度的关键策略。尽管过去的实验已经测定了ASDs中的表观溶出速率(分子和胶体药物),但在溶出过程中只有分子药物能够在体内被有效吸收。本研究旨在通过整合人工智能和基于生理的药代动力学(AI/PBPK)建模,开发一种预测ASD制剂体外(分子溶出)和体内(全身吸收)命运的模型。收集了238种ASD制剂,包括22种小分子药物和1693个药物分子溶出时间点,用于分子溶出预测。表格先验数据拟合网络(TabPFN)模型在六个机器学习框架中均表现出强大的预测性能,实现了0.116±0.020的低均方根误差(RMSE)和0.905±0.028的高决定系数(R)。然后,释放动力学模型架起了ASDs体外和体内溶出的桥梁。开发了三种上市ASD(诺氟沙星、普乐可复、灰黄霉素聚乙二醇)的PBPK模型,并以小于2的绝对平均倍数误差(AAFE)进行了验证。模拟的全身吸收与使用经典反卷积方法获得的结果具有高度相似性,相似因子(f)超过50。使用我们的框架对另外37种上市的ASD制剂进行了评估,大多数Cmax和AUC预测值落在两倍误差范围内,证明了我们的ASD AI/PBPK模型的高准确性和稳健性。本研究不仅为ASDs的合理设计和评估提供了一种实用且快速的计算工具,还显著推进了我们对分子溶出和全身吸收之间相互作用的理解,从而有助于优化药物递送系统。